Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2025)
Historic Operating Leases for Cartesian Therapeutics (RNAC) over the last 8 years, with Q3 2025 value amounting to $12.6 million.
- Cartesian Therapeutics' Operating Leases fell 1397.86% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.6 million, marking a year-over-year decrease of 1397.86%. This contributed to the annual value of $11.1 million for FY2024, which is 2666.97% up from last year.
- Per Cartesian Therapeutics' latest filing, its Operating Leases stood at $12.6 million for Q3 2025, which was down 1397.86% from $13.3 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Operating Leases registered a high of $14.9 million during Q2 2024, and its lowest value of $8.6 million during Q4 2021.
- Over the past 5 years, Cartesian Therapeutics' median Operating Leases value was $10.5 million (recorded in 2023), while the average stood at $11.2 million.
- Per our database at Business Quant, Cartesian Therapeutics' Operating Leases crashed by 1400.41% in 2021 and then soared by 3978.63% in 2024.
- Cartesian Therapeutics' Operating Leases (Quarter) stood at $8.6 million in 2021, then grew by 16.95% to $10.1 million in 2022, then dropped by 12.59% to $8.8 million in 2023, then grew by 26.67% to $11.1 million in 2024, then rose by 13.2% to $12.6 million in 2025.
- Its Operating Leases stands at $12.6 million for Q3 2025, versus $13.3 million for Q2 2025 and $14.1 million for Q1 2025.